Oncternal Therapeutics Inc (ONCT)
Market Open
2 Dec, 21:00
NASDAQ (CM) NASDAQ (CM) Primary $
0. 53
-0.17
-24.121%
$
1.56M Market Cap
- P/E Ratio
- Div Yield
644,135 Volume
-10.66 Eps
$ 0.69
Previous Close Want to track ONCT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Richard Vincent - Chief Financial Officer Jim Breitmeyer - President and Chief Executive Officer Salim Yazji - Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Kemp Dolliver - Brookline Capital Markets Operator Greetings and welcome to the Oncternal Therapeutics Second Quarter 2024 Financial Results Call. [Operator Instructions] As a reminder, this conference is being recorded.
Seekingalpha | 2 years ago
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates
Oncternal Therapeutics (ONCT) came out with a quarterly loss of $2.89 per share versus the Zacks Consensus Estimate of a loss of $3.03. This compares to loss of $3 per share a year ago.
Zacks | 2 years ago
